Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
Urinary Bladder Neoplasms|Immunotherapy
DRUG: Camrelizumab
The maximum dose of Camrelizumab for intravesical treatment, The maximum tolerated dose (MTD) of Camrelizumab that will be given intravesically to patients with BCG-refractory NMIBC(de-escalated doses of 200/150/100mg) and recommended for phase II studies (RP2D)., 3 months after trial initiation(Phase I)|Event-Free Survival (EFS), Recurrence of high-grade cancer (TaHG, T1HG, CIS), or disease progression to stage T2 or beyond or lymph node metastasis or distant metastasis, or the need for other treatment (including systemic chemotherapy, radical cystectomy, radiation therapy), and death from any cause., 3 months after patient treatment (Phase II)
Incidence of adverse events, Incidence of adverse events and treatment-related adverse events, Until progressive disease or death|Assessment of HGRF, High grade cancer recurrence free rate (HGFR) at 6 months and 1 year of treatment., 6 months and 1 year after patient enrollment|Assessment of RFS, Recurrence free survival (RFS) at 6 months and 1 year of treatment., 6 months and 1 year after patient enrollment|Assessment of PFS, Progression free survival (PFS) at 6 months and 1 year of treatment., 6 months and 1 year after patient enrollment|the predictive value of PD-1 expresssion, the predictive value of PD-L1 expression assessed in tumor tissue and urine sample obtained before and after Camrelizumab instillation., 1 year after patient enrollment
This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.